A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination With KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects.

Trial Profile

A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination With KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Jun 2010

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir; Lopinavir/ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms HEAT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Jul 2009 Results published in AIDS.
    • 10 Feb 2009 Results presented at CROI 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top